Skip to main content
Article thumbnail
Location of Repository

Effect of a Direct Thrombin Inhibitor Compared with Dalteparin and Unfractionated Heparin on Human Osteoblasts

By Tobias Winkler, Carsten Perka, Dörte Matziolis and Georg Matziolis
Topics: Article
Publisher: Bentham Open
OAI identifier:
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles


    1. (1997). A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats. Blood
    2. (1999). A histomorphometric evaluation of heparin-induced bone loss after discontinuation of heparin treatment in rats. Blood
    3. (1991). An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT.
    4. (2003). Changes in bone density during long-term administration of low-molecular-weight heparins or acenocoumarol for secondary prophylaxis of venous thromboembolism. Pathophysiol Haemost Thromb
    5. (2003). Clinical experience of melagatran/ximelagatran in major orthopaedic surgery. Thromb Res
    6. (1997). Effect of medication on biomechanical properties of rabbit bones: heparin induced osteoporosis. Clin Rheumatol
    7. (1996). Effect of syringe size on bruising following subcutaneous heparin injection.
    8. (2003). Effects of fondaparinux compared with dalteparin, enoxaparin and unfractionated heparin on human osteoblasts. Calcif Tissue Int
    9. (1995). Efficacy and safety of enoxaparin to prevent deep vein thrombosis after hip arthroplasty. Clin Orthop Relat Res
    10. (1988). Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res
    11. (1990). Heparin effect on bone density. Thromb Haemost
    12. (1979). Heparin-induced spinal fractures.
    13. (2002). Influence of unfractionated and low-molecular-weight heparin on bone healing: an animal model. Unfallchirurg
    14. (1978). Low-dose heparin for prevention of venous thromboembolism in total hip arthroplasty and surgical repair of hip fractures.
    15. (1993). Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin.
    16. (1994). Predisposing factors in fixation failure of femoral prostheses following primary Charnley low friction arthroplasty. A 10- to 20-year followup study. Clin Orthop Relat Res
    17. (1997). Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin.
    18. (2001). Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol
    19. (2003). Serious complication after subcutaneous injection of heparin for prophylaxis of thromboembolism. Case report. Unfallchirurg
    20. (2003). The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study.
    21. (1996). The effects of long-term heparin therapy during pregnancy on bone density. A prospective matched cohort study. Thromb Haemost
    22. (1998). The effects of standard and low molecular weight heparin on bone nodule formation in vitro. Thromb Haemost
    23. (1988). Total hip arthroplasty after renal transplantation. Long-term follow-up study and assessment of metabolic bone status.
    24. (1995). Total hip replacement in renal transplant patients.
    25. (2005). Ximelagatran--a promising new drug in thrombo-embolic disorders. Curr Pharm Des
    26. (2004). Ximelagatran: a novel oral direct thrombin inhibitor for long-term anticoagulation. Rev Cardiovasc Med

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.